HepaRx
Small Molecule Cancer Drugs
Health Tech & Life Sciences
Non Active, Jul 2018 ceased to operate
Company Overview
Snapshot
Founded in September 2014, HepaRx operated with 1–10 employees. The company received funding from FutuRx in a Seed round in May 2017.
Business overview
HepaRx is focused on developing small molecule cancer drugs. The company's core technology involves inhibiting heparanase (Hpa) enzymatic activity to prevent the spread of cancer cells, utilizing the Hpa crystal structure for drug design. HepaRx operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical industry with its oncology and biopharmaceutical solutions.
Company Intelligence Q&A
- What is HepaRx's primary focus?
- HepaRx is developing small molecule cancer drugs designed to inhibit heparanase (Hpa) enzymatic activity, aiming to stop the spread of cancer cells.
- When was HepaRx founded?
- HepaRx was founded in September 2014.
- What is the status of HepaRx?
- HepaRx is currently non-active, having ceased operations in July 2018.
- What is the company's product stage?
- HepaRx's product is in the R&D stage, focusing on drug design and development using the Hpa crystal structure.